



## *The International Hormone Society*

*www.intlhormonesociety.org*

### **References of Consensus 8 on Testosterone Therapy of Testosterone Deficiency in Women**

#### **I) Age-related decline of testosterone levels in women:**

##### **Senescence is associated with a reduction of the serum testosterone level in women**

1. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. *J Clin Endocrinol Metab.* 1995 Apr;80(4):1429-30

##### **Testosterone derives in women for more than 90% from the much quicker declining serum DHEA**

2. Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez JL, Candas B., DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. *Steroids*, 1998;63(5-6):322-8

#### **II) Testosterone treatment has beneficial actions in a wide variety of conditions in women:**

##### **1) Testosterone may improve psychic well-being in women**

##### **Lower quality of life and fatigue in women: the association with lower testosterone levels**

3. 323. Abrahamsson L, Hackl H, Lindstrom B, Sogn J. Long-term treatment of virilized women with cyproterone acetate. *Wien Klin Wochenschr.* 1981 Sep 18;93(17):552-6

##### **Quality of life in women: the improvement with testosterone treatment**

4. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *Menopause.* 2003 Sep-Oct;10(5):390-8

##### **Vasomotor symptoms in women: the improvement with testosterone treatment**

5. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. *Menopause.* 1999 Summer;6(2):138-46

##### **Depression in women: the association with lower testosterone levels**

6. Rohr UD. The impact of testosterone imbalance on depression and women's health. *Maturitas.* 2002 Apr 15;41 Suppl 1:S25-46

##### **Depression in women: the improvement with testosterone treatment**

7. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. *J Affect Disord.* 1988 Mar-Apr;14(2):177-87

##### **Negative symptoms in women: the association with lower serum testosterone levels**

8. Goyal RO, Sagar R, Ammini AC, Khurana ML, Alias AG. Negative correlation between negative symptoms of schizophrenia and testosterone levels *Ann N Y Acad Sci.* 2004 Dec;1032:291-4

### **Anxiety in women: the association with lower testosterone levels**

9. Landen M, Baghaei F, Rosmond R, Holm G, Bjornorp P, Eriksson E. Dyslipidemia and high waist-hip ratio in women with self-reported social anxiety. *Psychoneuroendocrinology*. 2004 Sep;29(8):1037-46 (Serum levels of total testosterone (1.6+/-0.8 vs. 2.2+/-1.1,  $P=0.013$ ) and free thyroxin (14+/-2 vs. 16+/-4,  $P=0.04$ ) were lower in subjects confirming social anxiety)

### **Anxiety in women: the improvement with testosterone treatment**

10. Montgomery JC, Appleby L, Brincat M, Versi E, Tapp A, Fenwick PB, Studd JW. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. *Lancet*. 1987 Feb 7;1(8528):297-9
11. van Honk J, Peper JS, Schutter DJ. Testosterone reduces unconscious fear but not consciously experienced anxiety: implications for the disorders of fear and anxiety. *Biol Psychiatry*. 2005 Aug 1;58(3):218-25

### **Memory loss and Alzheimer's disease in women: the association with lower testosterone levels**

12. Simpson E, Davis S. Why do the clinical sequelae of estrogen deficiency affect women more than men? *J Clin Endocrinol Metab*. 1998 Jun;83(6):2214

### **Memory in women: the improvement with testosterone treatment**

13. Wisniewski AB, Nguyen TT, Dobs AS. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women. *Horm Res*. 2002;58(3):150-5

### **Love in women: the association with higher testosterone in women**

14. Marazziti D, Canale D. Hormonal changes when falling in love. *Psychoneuroendocrinology*. 2004 Aug;29(7):931-6

### **Loss of sexual drive, sexual gratification, intercourse frequency in women: the association with lower testosterone levels**

15. Persky H, Lief HI, Miller WR, O'Brien CP. Plasma testosterone level and sexual behavior of couples. *Arch Sex Behav*. 1978 May; 7(3):157-73

### **Sexuality decline in women: the improvement with testosterone treatment**

16. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas*. 1995 Apr;21(3):227-36
17. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *Menopause*. 2003 Sep-Oct;10(5):390-8
18. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. *J Reprod Med*. 1998 Oct;43(10):847-56
19. Sarrel PM. Psychosexual effects of menopause: role of androgens. *Am J Obstet Gynecol*. 1999 Mar;180(3 Pt 2):S319-24
20. Penotti M, Sironi L, Cannata L, Vigano P, Casini A, Gabrielli L, Vignali M. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. *Fertil Steril*. 2001 Aug;76(2):235-40
21. Tuiten A, Laan E, Panhuysen G, Everaerd W, de Haan E, Koppeschaar H, Vroon P. Discrepancies between genital responses and subjective sexual function during testosterone substitution in women with hypothalamic amenorrhea. *Psychosom Med*. 1996 May-Jun;58(3):234-41
22. Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. *Arch Gen Psychiatry*. 2000 Feb;57(2):149-53
23. Shifren JL. The role of androgens in female sexual dysfunction. *Mayo Clin Proc*. 2004 Apr;79(4 Suppl):S19-24
24. Riley AJ. Life-long absence of sexual drive in a woman associated with 5-dihydrotestosterone deficiency. *J Sex Marital Ther*. 1999 Jan-Mar;25(1):73-8
25. Penotti M, Sironi L, Cannata L, Vigano P, Casini A, Gabrielli L, Vignali M. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. *Fertil Steril*. 2001 Aug;76(2):235-40

26. Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E, Pons F, Balasch J, Vanrell JA. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. *Maturitas*. 2000 Feb 15;34(2):161-8
27. Studd JWW, Collins WP, Chakravarti S. Estradiol and testosterone implants in the treatment of psychosexual problems in postmenopausal women. *Br J Obstet Gynaecol* 1977;84:314-5
28. Burger HG, Hailes J, Menelaus M. The management of persistent symptoms with estradiol-testosterone implants: clinical, lipid and hormonal results. *Maturitas* 1984;6:351-8
29. Burger HG, Hailes J, Nelson J, Menelaus M. Effect of combined implants of estradiol and testosterone on libido in postmenopausal women. *Br Med J* 1987;294:936-937
30. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. *Am J Obstet Gynecol*. 1985 Jan 15;151(2):153-60
31. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. *Psychosom Med*. 1985 Jul-Aug;47(4):339-51
32. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. *Psychosom Med* 1987 Jul-Aug;49(4):397-409
33. Dow MG, Hart DM, Forrest CA. Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study. *Br J Obstet Gynaecol* 1983 Apr;90(4):361-6

## **2) Testosterone may improve the physical appearance and body composition of women**

### **Sarcopenia in women: the association with lower testosterone levels**

34. Douchi T, Yoshimitsu N, Nagata Y. Relationships among serum testosterone levels, body fat and muscle mass distribution in women with polycystic ovary syndrome. *Endocr J*. 2001 Dec;48(6):685-9

### **Sarcopenia in women: the improvement with testosterone treatment**

35. Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. *Am J Physiol*. 1999 Feb;276(2 Pt 1):E317-25

### **Lean body mass in women: the association with lower testosterone levels**

36. Sowers MF, Beebe JL, McConnell D, Randolph J, Jannausch M. Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status. *Am J Epidemiol*. 2001 Feb 1;153(3):256-64
37. Douchi T, Yamamoto S, Oki T, Maruta K, Kuwahata R, Nagata Y. Serum androgen levels and muscle mass in women with polycystic ovary syndrome. *Obstet Gynecol*. 1999 Sep;94(3):337-40

### **Lean body mass in women: the improvement with testosterone treatment**

38. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. *J Clin Endocrinol Metab*. 2002 Apr;87(4):1509-16
39. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. *Menopause*. 2000 Nov-Dec;7(6):395-401
40. Floter A, Nathorst-Boos J, Carlstrom K, Ohlsson C, Ringertz H, Schoultz B. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. *Gynecol Endocrinol*. 2005 Mar;20(3):155-60

## **3) Testosterone may attenuate or slow down age-related diseases in women**

### **Atherosclerosis in women: the association with lower testosterone levels**

41. Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H, Szklo M. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. *Am J Epidemiol*. 2002 Mar 1;155(5):437-45
42. Bernini GP, Sgro' M, Moretti A, Argenio GF, Barlascini CO, Cristofani R, Salvetti A. Endogenous androgens and carotid intimal-medial thickness in women. *J Clin Endocrinol Metab*. 1999 Jun;84(6):2008-12

### **Atherosclerosis in women: the improvement with testosterone treatment**

43. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. *J Clin Endocrinol Metab.* 2001 Jan;86(1):158-61

### **Coronary artery disease in women: the association with lower testosterone levels**

44. Kaczmarek A, Reczuch K, Majda J, Banasiak W, Ponikowski P. The association of lower testosterone level with coronary artery disease in postmenopausal women. *Int J Cardiol.* 2003 Jan;87(1):53-7
45. Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H, Szklo M. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. *Am J Epidemiol.* 2002 Mar 1;155(5):437-45

### **Coronary artery disease in female subjects: the improvement with testosterone treatment**

46. Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, Chatterjee K. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. *Circulation.* 1996 Nov 15;94(10):2614-9
47. Lesser MA. Testosterone propionate therapy in one hundred cases of angina pectoris. *J Clin Endocrinol.* 1946;6:549-557.

### **Osteoporosis and osteopenia in women: the association with lower testosterone levels**

48. Deng X, Wang W, Wu X, Huang G, Peng J, Liao E, Wu H. Correlation between bone mineral density and sexual hormones in healthy Chinese women. *J Environ Pathol Toxicol Oncol.* 2000;19(1-2):167-9
49. Nilas L, Christiansen C. Bone mass and its relationship to age and the menopause. *J Clin Endocrinol Metab.* 1987;65:697-9
50. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri- and postmenopausal women. *J Clin Invest.* 1996;97:14-21
51. Simberg N, Titinen A, Silfrast A, Viinikka L, Ylikorkala O. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progesterin replacement. *J Clin Endocrinol Metab* 1995;81:646-51

### **Osteoporosis and osteopenia in women: the improvement with testosterone treatment**

52. Miller BE, De Souza MJ, Slade K, Luciano AA. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density. *Menopause.* 2000 Sep-Oct;7(5):318-26
53. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. *J Reprod Med.* 1999 Dec;44(12):1012-20
54. Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E, Pons F, Balasch J, Vanrell JA. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. *Maturitas.* 2000 Feb 15;34(2):161-8
55. Raisz EG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. *J Clin Endocrinol Metab.* 1995;81:37-43
56. Watts NB, Notelovitz M, Timmons MC. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. *Obstet Gynecol.* 1995;85:529-37
57. Savvas M, Studd JWW, Fogelman I, Dooley M, Montgomery J, Murby B. Skeletal effects of oral estrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. *Br Med J.* 1988;297:331-3
58. Savvas M, Sludd JWW, Norman S, Leather AT, Garnett, TJ. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post menopausal women who have previously received long-term oral oestrogens. *Br J Obstet Gynaecol.* 1992;99:757-60
59. Davis SR, McCloud PI, Strauss BJG, Burger HG. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas.* 1995;21:227-36
60. Kasra M, Grynblas MD. The effects of androgens on the mechanical properties of primate bone. *Bone.* 1995;17:265-70

### **Height loss and hip fractures in women: the association with lower testosterone levels**

61. Jassal SK, Barrett-Connor E, Edelstein S. Low bioavailable testosterone levels predict future height loss in postmenopausal women. *J Bone Min Res.* 1995;10(4):650-3
62. Davidson BJ, Ross RK, Paganini-Hill A, Hammond GD, Siiteri PK, Judd HL. Total and free estrogens and androgens in postmenopausal women with hip fractures. *J Clin Endocrinol Metab.* 1982 Jan;54(1):115-20

#### **Rheumatism in women: the association with lower testosterone levels**

63. Sambrook PN, Eisman JA, Champion GD, Pocock NA. Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. *Arthritis Rheum.* 1988;31(8):973-8

#### **Rheumatism in women: the improvement with testosterone treatment**

64. Booji A, Biewenga-Booji CM, Huber-Bruning O, Cornelis C, Jacobs JW, Bijlsma JW. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. *Ann Rheum Dis.* 1996 Nov;55(11):811-5

#### **Obesity in women: the improvement with testosterone treatment**

65. van Kesteren PJ, Asscheman H, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. *Clin Endocrinol (Oxf).* 1997 Sep;47(3):337-42
66. Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. *Am J Physiol.* 1999 Feb;276(2 Pt 1):E317-25

#### **Cancer in women: the association with lower testosterone levels**

67. Inutsuka S, Kodama Y, Natsuda Y, Kumashiro R, Maekawa T. Serum testosterone level of patients with gastric carcinoma before and after gastrectomy. *Cancer.* 1986 Dec 15;58(12):2675-9

#### **Cancer: the improvement with testosterone treatment?**

68. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. *Menopause.* 2004 Sep-Oct;11(5):531-535
69. Natrajan PK, Soumakis K, Gambrell RD Jr. Estrogen replacement therapy in women with previous breast cancer. *Am J Obstet Gynecol.* 1999 Aug;181(2):288-95
70. Deng X, Wang W, Wu X, Huang G, Peng J, Liao E, Wu H. Correlation between bone mineral density and sexual hormones in healthy Chinese women. *J Environ Pathol Toxicol Oncol.* 2000;19(1-2):167-9

### **III) Diagnosis of testosterone deficiency in women**

#### **Clinical testosterone evaluation in women**

71. Rivera-Woll LM, Papalia M, Davis SR, Burger HG. Androgen insufficiency in women: diagnostic and therapeutic implications. *Hum Reprod Update.* 2004 Sep-Oct;10(5):421-32 (*"key symptoms of the female androgen insufficiency syndrome include reduced libido, diminished well being and lowered mood"*)
72. Miller KK. Androgen deficiency in women. *J Clin Endocrinol Metab.* 2001 Jun;86(6):2395-401
73. Braunstein GD. Androgen insufficiency in women: summary of critical issues. *Fertil Steril.* 2002 Apr;77 Suppl 4:S94-9
74. Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, Richards SM, Suzuki T, Schaumberg DA, Sullivan RM, Dana MR. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. *Ann N Y Acad Sci.* 2002 Jun;966:211-22
75. Sullivan DA, Belanger A, Cermak JM, Berube R, Papas AS, Sullivan RM, Yamagami H, Dana MR, Labrie F. Are women with Sjogren's syndrome androgen-deficient? *J Rheumatol.* 2003 Nov;30(11):2413-9

#### **Serum androgen tests in women**

76. Fears TR, Ziegler RG, Donaldson JL, Falk RT, Hoover RN, Stanczyk FZ, Vaught JB, Gail MH. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. *Cancer Epidemiol Biomarkers Prev.* 2000 Apr;9(4):403-12

77. Gryngarten M, Bedecarras P, Ayuso S, Bergada C, Campo S, Escobar ME. Clinical assessment and serum hormonal profile in prepubertal hypertrichosis. *Horm Res.* 2000;54(1):20-5

#### ***Serum total testosterone in women***

78. Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ. Limitations of direct estradiol and testosterone immunoassay kits. *Steroids.* 2003 Dec;68(14):1173-8
79. Judd HL, Yen SS Serum androstenedione and testosterone levels during the menstrual cycle. *J Clin Endocrinol Metab* 1973 Mar;36(3):475-81
80. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. *Clin Chem.* 2003 Aug;49(8):1381-95
81. Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. *Eur J Endocrinol.* 2005 Mar;152(3):471-8
82. Herold DA, Fitzgerald RL. Immunoassays for testosterone in women: better than a guess? *Clin Chem.* 2003 Aug;49(8):1250-1
83. Nahoul K, Castanier M, Gervasi G, Scholler R. Assay of plasma progesterone and testosterone. Comparison of enzyme immunoassays and radio-immunoassays. *Ann Biol Clin (Paris).* 1989;47(3):127-34

#### ***Serum free testosterone in women***

84. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, Neubauer G, Klibanski A. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. *J Clin Endocrinol Metab.* 2004 Feb;89(2):525-33.

#### ***Serum dihydrotestosterone and androstenediol glucuronide in women***

85. Toscano V, Horton R. Circulating dihydrotestosterone may not reflect peripheral formation. *J Clin Invest.* 1987 Jun;79(6):1653-8
86. Greep N, Hoopes M, Horton R. Androstenediol glucuronide plasma clearance and production rates in normal and hirsute women. *J Clin Endocrinol Metab.* 1986 Jan;62(1):22-7
87. Rittmaster RS, Thompson DL, Listwak S, Loriaux DL. Androstenediol glucuronide isomers in normal men and women and in men infused with labeled dihydrotestosterone. *J Clin Endocrinol Metab.* 1988 Jan;66(1):212-6
88. Falsetti L, Rosina B, De Fusco D. Serum levels of 3alpha-androstenediol glucuronide in hirsute and non hirsute women. *Eur J Endocrinol.* 1998 Apr;138(4):421-4
89. Pasupuleti V, Lobo R, Horton R. Conversion of dihydrotestosterone to androstenediol glucuronide by female sexual skin. *Steroids.* 1988 Mar-Apr;51(3-4):269-82
90. Andre M, Valsamis J. Reference values for androstenediol glucuronide. *Clin Chem.* 1994 Jan;40(1):162.
91. Kirschner MA, Samojlik E, Szmal E. Clinical usefulness of plasma androstenediol glucuronide measurements in women with idiopathic hirsutism. *J Clin Endocrinol Metab.* 1987 Oct;65(4):597-601

#### ***Serum androsterone in women***

92. Zwicker H, Rittmaster RS. Androsterone sulfate: physiology and clinical significance in hirsute women. *J Clin Endocrinol Metab.* 1993 Jan;76(1):112-6
93. Thompson DL, Horton N, Rittmaster RS. Androsterone glucuronide is a marker of adrenal hyperandrogenism in hirsute women. *Clin Endocrinol (Oxf).* 1990 Mar;32(3):283-92

#### ***24-hour urine testosterone tests in women***

##### ***Urinary testosterone in women***

94. Doberne Y, New MI. Urinary androstenediol and testosterone in adults. *J Clin Endocrinol Metab.* 1976 Jan;42(1):152-4
95. Karila T, Kosunen V, Leinonen A, Tahtela R, Seppala T. High doses of alcohol increase urinary testosterone-to-epitestosterone ratio in females. *J Chromatogr B Biomed Appl.* 1996 Dec 6;687(1):109-16
96. Borts DJ, Bowers LD. Direct measurement of urinary testosterone and epitestosterone conjugates using high-performance liquid chromatography/tandem mass spectrometry. *J Mass Spectrom.* 2000 Jan;35(1):50-61
97. Makino H, Kobegawa A. Radioimmunoassay of urinary testosterone. *Horumon To Rinsho.* 1974 Jul;22(7):893-6

98. Bezverkhia TP. Method of determining urinary testosterone levels. *Lab Delo*. 1981;(5):285-8
99. Osada H, Osawa K, Makino T, Kandogawa A. Proceedings: Determination of urinary testosterone by radioimmunoassay. *Nippon Naibunpi Gakkai Zasshi*. 1974 Feb 20;50(2):190
100. Tresguerres JA, Tamm J. Urinary and plasma testosterone glucosiduronate measurement by a simple RIA method. *J Steroid Biochem*. 1979 Jul;11(1A):143-6
101. Sayo H, Hosokawa M. Spin immunoassay of urinary testosterone. *Yakugaku Zasshi*. 1980 Jan;100(1):56-60
102. Rudd BT, Rosenfield RL, Bongiovanni AM, Eberlein WR. The measurement of urinary testosterone glucuronide by competitive protein binding and validation by a double isotope derivative assay. *Steroids*. 1969 Feb;13(2):227-45
103. Futterweit W, Eng Y, Griboff SI. Gas chromatographic determination of urinary testosterone and epitestosterone glucuronide. *Mt Sinai J Med*. 1971 May-Jun;38(3):281-3
104. Venturelli E, Cavalleri A, Secreto G. Methods for urinary testosterone analysis. *J Chromatogr B Biomed Appl*. 1995; 671 (1-2): 363-80
105. Vermeulen A. A study of the urinary excretion of testosterone. *Verh K Vlaam Acad Geneesk Belg*. 1966;28(5):461-519
106. Andino N, James VH, Parker V, Rippon AE. Excretion of non-conjugated androstenedione and testosterone in human urine. *Steroids*. 1976 Dec;28(6):837-46
107. Wilkins RB, Carlson L. Qualitative studies of neutral 17-ketosteroids in normal subjects. *J Clin Endocrinol Metab*. 1952; 12: 647-3
108. Vestergaard P, Raabo E, Vedso S. Determination of urinary testosterone in men, women and children. *Clin Chim Acta*. 1966 Oct;14(4):540-52
109. Krawczynska H, Zachmann M, Prader A. Urinary testosterone glucuronide and sulphate in newborns and young infants. *Acta Endocrinol (Copenh)*. 1976 Aug;82(4):842-50
110. Raynaud E, Audran M, Pages JC, Brun JF, Fedou C, Chanal JL, Orsetti A. Study of urinary excretion of testosterone and epitestosterone glucuronides in children and adolescents *Pathol Biol (Paris)*. 1993 Feb;41(2):159-63
111. Bandelow B, Sengos G, Wedekind D, Huether G, Pilz J, Broocks A, Hajak G, Ruther E. Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder. *Pharmacopsychiatry*. 1997 Jul;30(4):113-7
112. Gode JD, Singh RH, Settiwar RM, Gode KD, Udupa KN. Increased urinary excretion of testosterone following a course of yoga in normal young volunteers. *Indian J Med Sci*. 1974 Apr-May;28(4-5):212-5
113. Yamamoto A, Ito M. Sebaceous gland activity and urinary androgen levels in children. *J Dermatol Sci*. 1992 Sep;4(2):98-104

#### ***Urinary 17-ketosteroids in women***

114. Lloyd CW, Lobotsky J, Segre EJ, Kobayashi T, Taymor ML, Batt RE. Plasma testosterone and urinary 17-ketosteroids in women with hirsutism and polycystic ovaries. *J Clin Endocrinol Metab*. 1966 Mar;26(3):314-24
115. Johnsen SG. Fractionation of urinary 17-ketosteroids. II. Normal values for men and women at different ages. *Acta Endocrinol (Copenh)*. 1956 Feb;21(2):146-56
116. Balassi GP. Examination of the true significance and semiological limitations of determination of urinary neutral steroid catabolites with 17-keto-steroid function in women: urinary elimination of 17-ketosteroids in physiological conditions in women from infancy to menopause. *Minerva Ginecol*. 1954 Jan 15;6(1):34-43
117. Ferraris G. Influence of physiological conditions on urinary excretion of 17-ketosteroids by women. *Minerva Ginecol*. 1952 Jan;4(1):18-24

#### ***Urinary androsterone***

118. Gilad S, Chayen R, Tordjman K, Kisch E, Stern N. Assessment of 5 alpha-reductase activity in hirsute women: comparison of serum androstanediol glucuronide with urinary androsterone and aetiocholanolone excretion. *Clin Endocrinol (Oxf)*. 1994 Apr;40(4):459-64

### **IV) Treatment of Testosterone Deficiency in women**

#### **Testosterone medications for women**

119. Buckler HM, Robertson WR, Wu FC. Which androgen replacement therapy for women? *J Clin Endocrinol Metab*. 1998 Nov;83(11):3920-4

#### ***Transdermal testosterone for women***

120. Singh AB, Lee ML, Sinha-Hikim I, Kushnir M, Meikle W, Rockwood A, Afework S, Bhasin S. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. *J Clin Endocrinol Metab.* 2006 Jan;91(1):136-44
121. Warnock JK, Swanson SG, Borel RW, Zipfel LM, Brennan JJ; ESTRATEST Clinical Study Group. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. *Menopause.* 2005 Jul-Aug;12(4):374-84
122. Mazer NA, Shifren JL. Transdermal testosterone for women: a new physiological approach for androgen therapy. *Obstet Gynecol Surv.* 2003 Jul;58(7):489-500
123. Slater CC, Souter I, Zhang C, Guan C, Stanczyk FZ, Mishell DR. Pharmacokinetics of testosterone after percutaneous gel or buccal administration. *Fertil Steril.* 2001 Jul;76(1):32-7
124. Javanbakht M, Singh AB, Mazer NA, Beall G, Sinha-Hikim I, Shen R, Bhasin S. Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. *J Clin Endocrinol Metab.* 2000 Jul;85(7):2395-401

#### ***Sublingual/buccal testosterone for women***

125. Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. *Arch Gen Psychiatry.* 2000 Feb;57(2):149-53
126. Wren BG, Day RO, McLachlan AJ, Williams KM. Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. *Climacteric.* 2003 Jun;6(2):104-11

#### ***Intramuscular injections of testosterone or nandrolone for women***

127. Sherwin BB, Gelfand MM, Schucher R, Gabor J. Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations. *Am J Obstet Gynecol.* 1987 Feb;156(2):414-9
128. Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, Baez A, Gupta S, Mattoo N. A comparison of androgens for anemia in patients on hemodialysis. *N Engl J Med.* 1981 Apr 9;304(15):871-5

#### **Testosterone treatment in women: dose and frequency**

129. Hirshland H, Hill J. Effect of the frequency of injection on the clinical responses of postmenopausal women to testosterone enanthate with estradiol valerate. *Am J Obstet Gynecol.* 1963 May 15;86:177-82

#### **Testosterone treatment in women: safety**

130. Barrett-Connor E, Timmons MC, Young R, Wiita B, Estratest Working Group. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. *J Women's Health* 1996;5:593-602
131. Sherwin BB, Gelfand MM, Schucher R, Gabor J. Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations. *Am J Obstet Gynecol.* 1987 Feb;156(2):414-9 (*"testosterone did not induce an increased atherogenic lipid profile"*)
132. Davison S, Thippawong J, Blanchard J, Liu K, Morishige R, Gonda I, Okikawa J, Adams J, Evans A, Otulana B, Davis S. Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. *J Clin Pharmacol.* 2005 Feb;45(2):177-84

#### **Testosterone treatment in women: side effects**

133. Maguire HC Jr. Facial hair growth over site of testosterone injection in women. *Lancet.* 1964 Apr 18;42:864
134. Gitlin N, Korner P, Yang HM. Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: a meta-analysis of eight clinical trials. *Menopause.* 1999 Fall;6(3):216-24

#### **Testosterone treatment in women: interferences**

135. Kuhn W, Staks T, Jutting G. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. *Contraception.* 1994 Dec;50(6):563-79
136. Mathur RS, Landgreve SC, Moody LO, Semmens JP, Williamson HO. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. *Maturitas.* 1985;7:129-33

137. Krug R, Psych D, Pietrowsky R, Fehm HL, Born J. Selective influence of menstrual cycle on perception of stimuli with reproductive significance. *Psychosom Med.* 1994;56:410-7
138. Castlo-Branco C, Martinez de Osaba MJ, Fortuny A, Iglesias X, Gonzalez-Merlo J. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. *J Reprod Med.* 1995;40:556-60
139. Goh HH, Wong PC, Ratnam SS. Effects of sex steroids on the positive estrogen feedback mechanism in intact women and castrate men. *J Clin Endocrinol Metab.* 1985 Dec;61(6):1158-64
140. Vermesh M, Silva PD, Rosen GF, Vijod AG, Lobo RA. Effect of androgen on adrenal steroidogenesis in normal women. *J Clin Endocrinol Metab.* 1988 Jan;66(1):128-30

**Testosterone treatment in women: follow-up**

141. Bird CE, Finnis W, Boroomand K, Murphy J, Clark AF. Kinetics of testosterone metabolism in normal postmenopausal women and women with breast cancer. *Steroids.* 1978 Oct;32(3):323-35
142. Bassindale T, Cowan DA, Dale S, Hutt AJ, Leeds AR, Wheeler MJ, Kicman AT. Effects of oral administration of androstenedione on plasma androgens in young women using hormonal contraception. *J Clin Endocrinol Metab.* 2004 Dec;89(12):6030-8
143. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. *Am J Obstet Gynecol.* 2005 Jun;192(6):2055-9